Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22545922 | 1.00 | TGM2 (0.45) | TGM2KMT2ARAB9ANPC1MEN1 | |
| SCHEMBL8088906 | 0.94 | KMT2A (0.44) | TGM2KMT2ARAB9ANPC1MEN1 | |
| SCHEMBL7750555 | 0.90 | — | — | |
| SCHEMBL27733678 | 0.82 | KMT2A (0.43) | TGM2KMT2ARAB9ANPC1MEN1 | |
| SCHEMBL7456594 | 0.81 | MAPT (0.64) | KMT2ARAB9AMEN1HTTSMN1; SMN2 | |
| SCHEMBL1783979 | 0.81 | KMT2A (0.44) | KMT2AHTTSMN1; SMN2MAPTTSHR | |
| SCHEMBL2187966 | 0.81 | KMT2A (0.48) | KMT2AMEN1HTTSMN1; SMN2MAPT | |
| SCHEMBL8448473 | 0.81 | KMT2A (0.40) | KMT2ARAB9ANPC1MEN1HTT | |
| SCHEMBL7536185 | 0.79 | KMT2A (0.42) | KMT2ARAB9AHTTSMN1; SMN2MAPT | |
| SCHEMBL5524889 | 0.77 | KMT2A (0.46) | KMT2ARAB9ANPC1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| EP-3141252-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-4238613-A | IMPARTING PHOTOSTABILITY AND OXIDATION AND HEAT RESISTANCE TO PLASTICS | CIBA-GEIGY CORPORATION (US) | 1980-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793817-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | TGM2 2489/4885KMT2A 2583/4885RAB9A 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.